Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome

Pharmacogenomics Journal

Volumn 14, Issue 1, 2014, Pages 54-62

  Stevens, A ^a   Clayton, P ^a   Tato L ^b   Yoo, H W ^c   Rodriguez Arnao, M D ^d   Skorodok, J ^e   Ambler, G R ^f   Zignani, M ^g   Zieschang, J ^h   Della Corte, G ^g   Destenaves, B ^g   Champigneulle, A ^g   Raelson, J ^i,k   Chatelain, P ^j  

^a ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF VERONA   (Italy)

^c University of Ulsan College of Medicine   (South Korea)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e SAINT PETERSBURG STATE PEDIATRIC MEDICAL UNIVERSITY   (Russian Federation)

^f CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^g MERCK SERONO S A   (Switzerland)

^h MERCK KGAA   (Germany)

ⁱ Genizon BioSciences Inc   (Canada)

^j UNIVERSITÉ LYON 1   (France)

^k Genizon BioSciences   (Canada)

more..

Author keywords

gene expression; genetic association; genetic marker; growth hormone; insulin like growth factor I

Indexed keywords

CYCLIN DEPENDENT KINASE 4; GLUCOCORTICOID RECEPTOR; HUMAN GROWTH HORMONE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; SOMATOMEDIN C RECEPTOR;

ALLELE; ARTICLE; CHILD; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GROWTH HORMONE DEFICIENCY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MARKER GENE; PHARMACOGENOMICS; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION; TURNER SYNDROME; WNT SIGNALING PATHWAY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE 4; FEMALE; GENE EXPRESSION PROFILING; GROWTH DISORDERS; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INFANT; INSULIN-LIKE GROWTH FACTOR I; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TRANSCRIPTOME; TURNER SYNDROME;

EID: 84893682671     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2013.14     Document Type: Article

References (39)

1. Park P, Cohen P. The role of insulin-like growth factor I monitoring in growth hormone-treated children. Horm Res 2004; 62(Suppl 1): 59-65.
2. [No authors listed]. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 2001; 86: 1868-1870.
3. Cohen P, Bright GM, Rogol AD, Kappelgaard AM, Rosenfeld RG. Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. J Clin Endocrinol Metab 2002; 87: 90-98.
4. Cohen P, Germak J, Rogol AD, Weng W, Kappelgaard AM, Rosenfeld RG. Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children. J Clin Endocrinol Metab 2010; 95: 2089-2098.
5. Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab 2007; 92: 2480-2486.
6. Copeland KC, Underwood LE, Van Wyk JJ. Induction of immunoreactive somatomedin C human serum by growth hormone: dose-response relationships and effect on chromatographic profiles. J Clin Endocrinol Metab 1980; 50: 690-697.
7. Kristrom B, Aronson AS, Dahlgren J, Gustafsson J, Halldin M, Ivarsson SA et al. Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature. J Clin Endocrinol Metab 2009; 94: 483-490.
8. Ranke MB, Schweizer R, Elmlinger MW, Weber K, Binder G, Schwarze CP et al. Relevance of IGF-I, IGFBP-3, and IGFBP-2 measurements during GH treatment of GH-deficient and non-GH-deficient children and adolescents. Horm Res 2001; 55: 115-124.
9. Clayton P, Chatelain P, Yoo HW, Rodriguez-Arnao MD, Salles JP, Lopez-Siguero JP et al. Single nucleotide polymorphisms (SNPs) associated with, and predictive of, growth response after 1 and 2 years on growth hormone (GH) therapy in girls with Turner syndrome (TS). Horm Res Paediatr 2011; 76: 97 (abstract P1-d1-308).
10. Chatelain P, Clayton P, Quinteiro S, Colle M, Cicognani A, Weill J et al. Single nucleotide polymorphisms (SNPs) associated with, and predictive of, growth response after 1 and 2 years on growth hormone (GH) therapy in children with GH deficiency (GHD). Horm Res Paediatr 2011; 76: 101 (abstract P1-d2-319).
11. Buckway CK, Guevara-Aguirre J, Pratt KL, Burren CP, Rosenfeld RG. The IGF-I generation test revisited: a marker of GH sensitivity. J Clin Endocrinol Metab 2001; 86: 5176-5183.
12. Rudman D, Kutner MH, Blackston RD, Cushman RA, Bain RP, Patterson JH. Children with normal-variant short stature: treatment with human growth hormone for six months. N Engl J Med 1981; 305: 123-131.
13. van Teunenbroek A, de Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Delemarre-van de Waal HA et al. Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. Dutch Working Group on Growth Hormone. J Clin Endocrinol Metab 1996; 81: 4013-4021.
14. Bakker B, Frane J, Anhalt H, Lippe B, Rosenfeld R. Height velocity targets from the National Cooperative Growth Study for first-year growth hormone responses in short children. J Clin Endocrinol Metab 2008; 93: 352-357.
15. Ranke MB, Lindberg A. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab 2010; 95: 1229-1237.
16. Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K et al. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin Endocrinol Metab 1999; 84: 1174-1183.
17. Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K et al. Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. KIGS International Board. Kabi International Growth Study. J Clin Endocrinol Metab 2000; 85: 4212-4218.
18. Wikland KA, Kristrom B, Rosberg S, Svensson B, Nierop AF. Validated multivariate models predicting the growth response to GH treatment in individual short children with a broad range in GH secretion capacities. Pediatr Res 2000; 48: 475-484.
19. Sybert VP, McCauley E. Turners syndrome. N Engl J Med 2004; 351: 1227-1238.
20. Elmlinger MW, Kuhnel W, Weber MM, Ranke MB. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 2004; 42: 654-664.
21. Haw R, Hermjakob H, DEustachio P, Stein L. Reactome pathway analysis to enrich biological discovery in proteomics data sets. Proteomics 2011; 11: 3598-3613.
22. Yu H, Kim PM, Sprecher E, Trifonov V, Gerstein M. The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS Comput Biol 2007; 3: e59.
23. Sun J, Zhao Z. A comparative study of cancer proteins in the human proteinprotein interaction network. BMC Genomics 2010; 11(Suppl 3): S5.
24. Croft D, OKelly G, Wu G, Haw R, Gillespie M, Matthews L et al. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res 2011; 39: D691-D697.
25. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 2011; 27: 431-432.
26. Zhu BM, Kang K, Yu JH, Chen W, Smith HE, Lee D et al. Genome-wide analyses reveal the extent of opportunistic STAT5 binding that does not yield transcriptional activation of neighboring genes. Nucleic Acids Res 2012; 40: 4461-4472.
27. Uesugi M, Verdine GL. The alpha-helical FXXPhiPhi motif in p53: TAF interaction and discrimination by MDM2. Proc Natl Acad Sci USA 1999; 96: 14801-14806.
28. Wang S, Guo M, Ouyang H, Li X, Cordon-Cardo C, Kurimasa A et al. The catalytic subunit of DNA-dependent protein kinase selectively regulates p53-dependent apoptosis but not cell-cycle arrest. Proc Natl Acad Sci USA 2000; 97: 1584-1588.
29. Choi H, Pavelka N. When one and one gives more than two: challenges and opportunities of integrative omics. Front Genet 2011; 2: 105.
30. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ et al. A network-based analysis of systemic inflammation in humans. Nature 2005; 437: 1032-1037.
31. Newman ME. Modularity and community structure in networks. Proc Natl Acad Sci USA 2006; 103: 8577-8582.
32. Hochberg Z. Mechanisms of steroid impairment of growth. Horm Res 2002; 58(Suppl 1): 33-38.
33. van Rossum EF, Voorhoeve PG, te Velde SJ, Koper JW, Delemarre-van de Waal HA, Kemper HC et al. The ER22/23EK polymorphism in the glucocorticoid receptor gene is associated with a beneficial body composition and muscle strength in young adults. J Clin Endocrinol Metab 2004; 89: 4004-4009.
34. Finken MJ, Meulenbelt I, Dekker FW, Frolich M, Walther FJ, Romijn JA et al. Abdominal fat accumulation in adults born preterm exposed antenatally to maternal glucocorticoid treatment is dependent on glucocorticoid receptor gene variation. J Clin Endocrinol Metab 2011; 96: E1650-E1655.
35. Binnerts A, Deurenberg P, Swart GR, Wilson JH, Lamberts SW. Body composition in growth hormone-deficient adults. Am J Clin Nutr 1992; 55: 918-923.
36. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-2170.
37. Mehls O, Himmele R, Homme M, Kiepe D, Klaus G. The interaction of glucocorticoids with the growth hormone-insulin-like growth factor axis and its effects on growth plate chondrocytes and bone cells. J Pediatr Endocrinol Metab 2001; 14(Suppl 6): 1475-1482.
38. Agha A, Monson JP. Modulation of glucocorticoid metabolism by the growth hormone-IGF-1 axis. Clin Endocrinol (Oxf) 2007; 66: 459-465.
39. Rosenfeld RG. Editorial: the pharmacogenomics of human growth. J Clin Endocrinol Metab 2006; 91: 795-796.